A
Alcista
Alcista · 25%TXG
$7.67
Precio del escenario
$69.890
+0.028 (+0.04%)Al cierre
Loading chart…
- Máximo
- 72.480
- Apertura
- 71.480
- Precio medio ponderado por volumen
- 70.29
- Volumen
- 2.53M
- Capitalización
- 2.38B
- Mínimo
- 68.500
- Importe
- 177.65M
- EV/EBITDA, TTM
- -8.95
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Métricas de valoración
El PER previsto actual de 10X Genomics Inc (TXG) es -9.54, frente a su media de 5 años de -47.51.
Escenarios de precio de Alphio AI para TXG
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con TXG en cartera
Cronología de eventos
Noticias
9.510-17stocktwitsAnalysis of Ark's Portfolio Performance in Q3
9.510-13PRnewswire10x Genomics to Report Q3 Financial Results on November 5, 2026
2.010-12FoolHealthcare Stocks Outperform Magnificent Seven
7.510-07PRnewswire10x Genomics Partners with Fred Hutch to Advance Cancer Research
7.510-07Newsfilter10x Genomics Partners with Fred Hutch to Advance Cancer Research
Preguntas frecuentes sobre TXG, respondidas por Alphio AI
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Comunidad
Más ↗
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.